GLP-1 medications transform obesity and diabetes treatment

New injectable medications, specifically GLP-1 receptor agonists, are transforming the clinical approach to obesity and type 2 diabetes. These drugs mimic natural hormones to increase insulin secretion, delay gastric emptying, and influence brain areas related to satiety, leading to significant weight reduction. Clinical trials show average weight losses of approximately 15% with semaglutide and over 20% with tirzepatide.

However, medical experts emphasize that these treatments are not a definitive cure for obesity, which is a chronic and recurrent disease. Patients frequently regain weight after discontinuing the medication. Common side effects include nausea, vomiting, diarrhea, and constipation.

To ensure long-term success and avoid the ‘rebound effect,’ specialists recommend a structured strategy. Dr. Nataniel Viuniski highlights the importance of prioritizing protein, vitamins, and minerals to preserve muscle mass and prevent nutritional deficiencies. Dr. Einar Rodríguez Lahoz notes that while these therapies can reduce serious cardiovascular and renal events, dosage must be individualized to manage digestive side effects.